Cleared Traditional

K191296 - Pointe Scientific Creatinine Kinase (CK...

K191296 is the FDA 510(k) clearance for Pointe Scientific Creatinine Kinase (CK... by Medtest DX. It is a Class 2 Chemistry device (product code CGS) cleared through the Traditional 510(k) pathway after a 455-day FDA review.

K191296 · Medtest DX · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2020
Decision
455d
Days
Class 2
Risk

K191296 is an FDA 510(k) clearance for the Pointe Scientific Creatinine Kinase (CK) Reagent Set. Classified as Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes (product code CGS), Class II - Special Controls.

Submitted by Medtest DX (Lincoln Park, US). The FDA issued a Cleared decision on August 11, 2020 after a review of 455 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1215 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Medtest DX devices

Submission Details

510(k) Number K191296 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 14, 2019
Decision Date August 11, 2020
Days to Decision 455 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
367d slower than avg
Panel avg: 88d · This submission: 455d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1215
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes

All 99
Devices cleared under the same product code (CGS) and FDA review panel - the closest regulatory comparables to K191296.
SEKURE Creatine Kinase Assay
K182702 · Sekisui Diagnostics P.E.I., Inc. · Apr 2019
ADVIA Chemistry Creatine Kinase (CK_L) Assay, ADVIA Chemistry Enzyme 3 Calibrator
K160724 · Siemens Healthcare Diagnostics, Inc. · Sep 2016
RANDOX LIQUID CK-MB, RANDOX CK-MB CALIBRATOR
K123977 · Randox Laboratories, Ltd. · Nov 2013
DIMENSION VISTA CREATINE KINASE FLEX REAGENT CARTRIDGE AND DIMENSION VISTA CREATINE KINASE MB FLEX REAGENT CARTRIDGE
K083465 · Siemens Healthcare Diagnostics · Feb 2009
DIMENSION CKI FLEX REAGENT CARTRIDGE, DIMENSION MBI FLEX REAGENT CARTRIDGE, AND CKI/MBI CALIBRATOR, MODELS DF38, DF32
K081731 · Siemens Healthcare Diagnostics · Aug 2008
CREATINE KINASE LIQUID REAGENT, MODEL C519-440
K072548 · Teco Diagnostics · Apr 2008